BioSpace

Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release.

作者 BioSpace

1 分钟阅读
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察